Perspectives in Medicinal Chemistry
Synopsis: An open access, peer reviewed electronic journal that covers drug design in the form of commentaries and reviews which do not require disclosure of proprietary information.
Indexing: Pubmed, Pubmed Central, Embase, Google Scholar, CAS, DOAJ, OAIster
Processing time: Decision in 2 weeks for 90% of papers.
Latest news:
Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
Cecilie Johannessen Landmark1 and Svein I. Johannessen2
1Cecilie Johannessen Landmark, Associate Professor, Dept. of Pharmacy, Faculty of Health Sciences, Oslo University College, Pilestredet 50, N-0167 Oslo, Norway. 2Svein I. Johannessen, Director of Research. The National Center for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, Norway.
Abstract
Introduction: A large number of antiepileptic drugs (AEDs) are available today, but they may not be satisfactory regarding clinical efficacy, tolerance, toxicity or pharmacokinetic properties. The purpose of this review is to focus upon the rationale behind the chemical modifications of several recently marketed AEDs or drugs in development and to categorize them according to the main purposes for the improvements: better efficacy or tolerability accompanied by improved pharmacokinetic properties.
Material and Method: AEDs that have been chemically modified to new derivatives during the last years are reviewed based on recent publications and PubMed-searches.
Results and Discussion: Improvement in pharmacokinetic parameters may affect both tolerability and efficacy. Modifications to improve tolerability include various valproate analogues, divided into aliphatic amides, cyclic derivatives or amino acid conjugates. Furthermore, there are the carbamazepine analogues oxcarbazepine and eslicarbazepine, the felbamate analogues fl uorofelbamate and carisbamate (RWJ 33369), and the lamotrigine analogue JZP-4. The levetiracetam analogues brivaracetam and seletracetam and the derivatives of gabapentin, pregabalin and XP13512, have improved selectivity compared to their parent compounds. Other new drugs have new mechanisms of action related to GABA and glutamate receptors; the glutamate antagonists like topiramate (talampanel and NS-1209), and GABAA receptor agonists, benzodiazepine or progesterone analogues (ELB-139 and ganaxolone).
Conclusion: Further challenges for development of new AEDs include investigations of target molecules affected by pathophysiological processes and detailed structure-activity relationships with focus on stereoselectivity. These potential drugs may become of importance in future drug therapy in epilepsy and other CNS disorders.
Readers of this also read:
- Lunasin: A Novel Cancer Preventive Seed Peptide
- Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
- Effects of FK506 on Ca2+ Release Channels (Review)
- 26/May/2009
Aminoglycosides: Molecular Insights on the Recognition of RNA and Aminoglycoside Mimics
- 28/Apr/2009
Perspectives on Using Physcomitrella Patens as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates
- 04/Mar/2009
Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- 09/May/2008
The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
- 10/Apr/2008
Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- 10/Apr/2008
Lunasin: A Novel Cancer Preventive Seed Peptide
- 25/Mar/2008
Effects of FK506 on Ca2+ Release Channels (Review)
- 18/Mar/2008
Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
- 07/Mar/2008
Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
- 14/Feb/2008
Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
- 10/Feb/2008
The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer
- 18/Jan/2008
Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases
- 11/Dec/2007
Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
- 11/Dec/2007
The pKa Distribution of Drugs: Application to Drug Discovery
- 17/Sep/2007
FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
- 06/Sep/2007
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
- 26/Jun/2007